

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-103. (Canceled)

104. (Previously Presented) A polypeptide consisting of an immunogenic portion of native WT1, wherein the immunogenic portion consists of the contiguous amino acids of SEQ ID NO:2.

105.-106. (Canceled)

107. (Previously Presented) A composition comprising an immunogenic portion of native WT1, wherein the immunogenic portion consists of the contiguous amino acids of SEQ ID NO:2.

108. (Previously Presented) A composition comprising an immunogenic portion of native WT1, wherein the immunogenic portion consists of the contiguous amino acids of SEQ ID NO:2, in combination with a non-specific immune response enhancer.

109. (Previously Presented) A composition according to claim 108, wherein the non-specific immune response enhancer is an adjuvant.

110. (Previously Presented) A composition comprising:

(a) a WT1 polypeptide consisting of an immunogenic portion of a native WT1; and

(b) a non-specific immune response enhancer that preferentially enhances a T cell response in a patient;

wherein said immunogenic portion consists of the contiguous amino acids of SEQ ID NO:2.

111. (Previously Presented) A composition according to claim 110, wherein the non-specific immune response enhancer is selected from the group consisting of Montanide ISA50, Seppic Montanide ISA 720, a cytokine, a microsphere, dimethyl dioctadecyl ammoniumbromide (DDA) based adjuvants, AS-1, AS-2, Ribi Adjuvant system based adjuvant, QS21, saponin based adjuvants, Syntex adjuvant in its microfluidized form, MV, ddMV, immune stimulating complex (iscom) based adjuvants, and inactivated toxins.

112. (Previously Presented) The composition of claim 111, wherein said cytokine is selected from the group consisting of GM-CSF and Flt3-ligand.